PROJECT44
12.2.2020 09:02:16 CET | Business Wire | Press release
project44, the global leader in advanced visibility for shippers and logistics service providers, has experienced significant growth across Europe following several recent announcements, including opening an office in Paris , adding several new team members , and building partnerships with global technology leaders .
Since acquiring Europe’s leading visibility provider, GateHouse Logistics, in 2018, project44 has increased global growth reaching more than 300 enterprise customers with over 20% in Europe, including leading brands such as Amazon, Coop, and Yazaki.
“With an increased need for real-time data and visibility across the entire supply chain, shippers and logistics service providers need a single global provider,” said Michael Gross, Director IT, Supply Chain and Logistics at Yazaki. “We’re excited for project44’s network to grow in Europe and beyond. Their plans for expansion are critical for supporting our global supply chain.”
With coverage in about 50 countries, integrations with over 760 telematics providers, and partnerships with global technology leaders such as SAP, project44 enables customers to tap into the most extensive visibility network across North America and Europe. With European carrier onboarding available in 16 languages and applications in 14 languages, p44’s comprehensive support ensures customers see the ROI of visibility in the fastest way possible.
To accelerate this European growth, project44 opened a Paris office in December of 2019 and has since retained several key hires for continued European expansion, reaching over 80 European-based employees in Aalborg, Amsterdam, Frankfurt, and Milan.
New team members include Regional VP of Sales Mickael Devena , Value Engineering Director Jatin Garg , Head of European Marketing Lorenzo Stranges, and Strategic Account Director Marco Tarpi . Devena and Garg bring extensive experience in transportation visibility from their time at Shippeo, while Stranges and Tarpi come from global SaaS leaders, including DocuSign and IBM respectively.
Michel Stekelenburg will also join the team as the Strategic Account Director for the Benelux region. In addition to several roles in supply chain technology, Stekelenburg serves as the President of the Benelux Roundtable for the Council of Supply Chain Management Professionals (CSCMP).
To lead this growing team, project44 has promoted Executive Vice President of Operations, Jørgen B Nielsen, to General Manager of Europe. With more than 20 years of experience with technical challenges and project execution in IT and telecom, Jørgen led GateHouse Logistics through rapid growth as Chief Operating Officer.
“Building on the GateHouse Logistics’s decade of significant success and expertise, project44 has continued to expand the European visibility market, delivering a seamless product and experience for our global customers,” said Jørgen. “As supply chains increase logistics and transportation operations across geographies, project44 will continue to expand globally and provide the coverage our customers need to effectively run their businesses.”
With over $110 million USD in capital, project44 will continue to explore additional international growth to deliver a seamless transportation visibility offering for global supply chains. By partnering with leading global carriers, project44 has already started gaining coverage beyond North America and Europe in Turkey, Russia, Ukraine, and Belarus. The visibility provider will also begin extending tracking connections in Morocco.
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations are able to increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Truckload, Rail, Intermodal, and Ocean. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005086/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom